Drug Profile
Research programme: cancer therapeutics - Isomerase Therapeutics
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Biotica Technology
- Developer Isomerase Therapeutics
- Class Macrolides
- Mechanism of Action G protein-coupled receptor GPR78 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in United Kingdom
- 08 Aug 2011 Cancer therapeutics programme available for partnering/licensing following preclinical proof-of-concept studies. http://www.biotica.com
- 27 Jan 2011 Early research is ongoing in the United Kingdom